Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Connect Biopharma Holdings LtdCNTB · Entity 6516 | Senior Vice President, Finance | March 16, 2026 | March 16, 2026 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | VP, Chief Accounting Officer | January 19, 2024 | January 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Connect Biopharma Holdings Ltd
Report date March 16, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 45,189 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 45,189 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2034-08-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2034-12-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2035-07-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2035-12-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.
F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.
HERON THERAPEUTICS, INC. /DE/
Report date January 19, 2024 · Filed January 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.09 · Expires 2034-01-19 | Direct | 41,078 |
Reported balance
After 2024-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-19 · Grant · Acquired 41,078 · Balance 41,078 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (01/19/2024). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,846 |
Reported balance
After 2024-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-19 · Grant · Acquired 6,846 · Balance 6,846 F2: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (01/19/2024).
F2: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 13, 2022 Filed Jan 14, 2022 22:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 966 | $8.30 | $8,017.80 |
DisclosureSEC source: 0001209191-22-003360 · doc4.xml · nonDerivative · entry 3 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,716 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003360 · doc4.xml · nonDerivative · entry 2 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003360 · doc4.xml · nonDerivative · entry 1 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 23,424 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060549 · doc4.xml · derivative · entry 5 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,424 Underlying: Common Stock · 23,424 shares Expires not disclosed F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 13,013 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001209191-21-060549 · doc4.xml · derivative · entry 4 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,013 Underlying: Common Stock · 13,013 shares Expires 2031-10-13 F4 · derivative.exercise_date: The stock option vests and becomes exercisable monthly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that the stock option will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060549 · doc4.xml · derivative · entry 3 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,625 Underlying: Common Stock · 552 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 191 | $10.55 | $2,015.05 |
DisclosureSEC source: 0001209191-21-060549 · doc4.xml · nonDerivative · entry 2 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,197 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060549 · doc4.xml · nonDerivative · entry 1 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046788 · doc4.xml · derivative · entry 4 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,177 Underlying: Common Stock · 552 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 191 | $13.48 | $2,574.68 |
DisclosureSEC source: 0001209191-21-046788 · doc4.xml · nonDerivative · entry 3 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,836 F3 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046788 · doc4.xml · nonDerivative · entry 2 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 30, 2021 Filed Jul 15, 2021 20:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 1,530 | $13.90 | $21,263.18 |
DisclosureSEC source: 0001209191-21-046788 · doc4.xml · nonDerivative · entry 1 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,475 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2021. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:52 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026842 · doc4.xml · derivative · entry 3 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,729 Underlying: Common Stock · 552 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:52 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 191 | $16.66 | $3,182.06 |
DisclosureSEC source: 0001209191-21-026842 · doc4.xml · nonDerivative · entry 2 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,945 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:52 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-026842 · doc4.xml · nonDerivative · entry 1 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:26 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003794 · doc4.xml · derivative · entry 3 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,281 Underlying: Common Stock · 552 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:26 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 227 | $18.16 | $4,122.32 |
DisclosureSEC source: 0001209191-21-003794 · doc4.xml · nonDerivative · entry 2 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,584 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:26 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003794 · doc4.xml · nonDerivative · entry 1 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:35 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 8,833 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054914 · doc4.xml · derivative · entry 2 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833 Underlying: Common Stock · 8,833 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:35 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 103,000 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001209191-20-054914 · doc4.xml · derivative · entry 1 Peraza Lisa · CIK 0001828266 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Stock · 103,000 shares Expires 2030-10-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.